ABOUT ME
Kati Räsänen, PhD, MAS
Being an independent consultant allows me to combine my two passions:
Advancing innovative cancer treatments and fostering people-oriented leadership culture.
Cancer therapeutics
With over 20 years in cancer research and drug discovery, I harness my knowledge to support VCs, start-ups and biotechs building their cancer therapeutics pipeline. My expertise lies in target identification, validation, drug discovery and development to the commencement of clinical trials. I am proficient in antibody-based therapeutic modalities such as ADCs and bispecifics, as well as small molecule therapies.
Leadership and culture
Enhancing the value of a company lies in its people, as they are the company's most valuable asset. I guide leaders in fostering a people-centric culture, providing guidance on effective leadership, change management, and team dynamics. Empowered by personal insights and a Master's degree in Leadership Psychology.
Resilient Collective offers a free gateway to biotech's leading independent consultants.
Handpicked for excellence.
Every member of Resilient Collective is curated to ensure they meet the highest standards of professionalism, expertise, and integrity.
Before transitioning to an Independent Consultant role, my career journey involved spearheading innovation in cutting-edge cancer treatments at following positions:
- Director of ADC Discovery / Pharmacology at Sotio Biotech (CZ)
- Head of Antibody-Drug Conjugates at Orion Pharma (FI)
- Senior Scientist at University of Helsinki (FI)
- Senior Scientist at Biosceptre International (UK)
- Post doc at Wistar Institute (US)
- PhD student at University of Helsinki (FI)
- Scientific Officer at Institute of Cancer Research (UK)
RECOGNIZED EXCELLENCE
Qualifications
MSc in
Biotechnology
2003, University of Jyväslylä
PhD in
Cancer Biology
2010, University of Helsinki
MAS in
Leadership Psychology
2025, University of Lapland
Additionally, I have obtained the official
Objectives and Key Results (OKR) Certification: Leadership and Goal Setting
from Measure What Matters via Coursera
More about my work
Treffen Media workshops 13 & 15 May 2026:
Beacon Intelligence database:
I serve as one of their key opinion leaders (KOLs) ensuring the database remains at the cutting edge
Beacon on-demand webinar: ADC Fireside Chat – Is a booming landscape a double-edged sword?
Pharmaron on-demand webinar: DMPK for ADCs: Measure the Parts, Model the Whole, Decide Early
16th WADC London 2026 Workshop:
16th WADC San Diego 2025 Workshop:
ADC Target 101: Keeping up to date with cutting-edge anti-tumor target discovery & validation
Recent publications and patents:
Anti-lrrc15 antibodies and uses thereof
Michaela Fojtu, Shohag Bhargava, Sarka Stehlikova, Tomas Zimmermann, Iva Valentova, Kati Räsänen, Ulrich Moebius, Lukas Fojtik, Lenka Kyrych Sadílková, Eva Nedvedova, Jakub Macosek, Katerina Krizova, Hana Freislebenova, Lukas Bammert, Roger Beerli. WO2026093513A1
Iva Valentová, Lenka Kyrych Sadílková, Lukas Bammert, Lorenz Waldmeier, Roger Beerli, Ilona Procházková, Filip Jabůrek, Tatiana Spitzová, Eliška Kohelová, Kati Räsänen, Ulrich Moebius & Radek Špíšek
BMC Cancer(2026). https://doi.org/10.1186/s12885-026-16185-x
Synthesis of Site-Specific Antibody-[60]Fullerene-Oligonucleotide Conjugates for Cellular Targeting.
Äärelä A, Räsänen K, Holm P, Salo H, Virta P. ACS Appl. Bio Mater.2023, 6, 8, 3189–3198
Kati Räsänen, Ilona Prochazkova, Michaela Fojtu, Lenka Kyrych Sadilkova, Ulrich Mobius. WO2025078686A1
